SIGA Technologies, Inc. (SIGA)
USD 5.98
(1.01%)
USD 5.98
(1.01%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 335.99 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 75.54 Million USD | 6.33% |
| 2017 | 71.05 Million USD | 6.76% |
| 2016 | 66.55 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 1.98 Million USD | -49.69% |
| 2012 | 3.95 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 22.8 Thousand USD | -78.62% |
| 2005 | 106.7 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 848.57 Thousand USD | 69.72% |
| 1999 | 500 Thousand USD | -28.57% |
| 1998 | 700 Thousand USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 837.08 Thousand USD | 0.0% |
| 2024 Q2 | 1.12 Million USD | 0.0% |
| 2023 FY | 335.99 Thousand USD | 0.0% |
| 2023 Q1 | 1.39 Million USD | 0.0% |
| 2023 Q2 | 1.24 Million USD | -11.06% |
| 2023 Q3 | 1.08 Million USD | -12.6% |
| 2023 Q4 | 335.99 Thousand USD | -69.07% |
| 2022 Q1 | 1.98 Million USD | 0.0% |
| 2022 Q2 | 1.84 Million USD | -7.3% |
| 2022 Q3 | 1.69 Million USD | -7.99% |
| 2022 Q4 | - USD | -100.0% |
| 2022 FY | - USD | 0.0% |
| 2021 Q4 | - USD | -100.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q3 | 2.3 Million USD | -4.27% |
| 2021 Q1 | 1.83 Million USD | 0.0% |
| 2021 Q2 | 2.4 Million USD | 31.03% |
| 2020 Q2 | 2.15 Million USD | -5.47% |
| 2020 Q4 | - USD | -100.0% |
| 2020 Q3 | 2.02 Million USD | -5.86% |
| 2020 FY | - USD | 0.0% |
| 2020 Q1 | 2.27 Million USD | 0.0% |
| 2019 Q1 | 76.65 Million USD | 1.47% |
| 2019 Q3 | 78.91 Million USD | 1.46% |
| 2019 Q2 | 77.77 Million USD | 1.46% |
| 2019 FY | - USD | -100.0% |
| 2019 Q4 | - USD | -100.0% |
| 2018 Q2 | 73.28 Million USD | 1.55% |
| 2018 Q4 | 75.54 Million USD | 1.52% |
| 2018 Q1 | 72.15 Million USD | 1.56% |
| 2018 FY | 75.54 Million USD | 6.33% |
| 2018 Q3 | 74.41 Million USD | 1.55% |
| 2017 Q3 | 69.91 Million USD | 1.65% |
| 2017 FY | 71.05 Million USD | 6.76% |
| 2017 Q1 | 67.66 Million USD | 1.67% |
| 2017 Q2 | 68.78 Million USD | 1.66% |
| 2017 Q4 | 71.05 Million USD | 1.62% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | 66.55 Million USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | 66.55 Million USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q3 | 499.53 Thousand USD | -49.93% |
| 2014 Q2 | 997.69 Thousand USD | -33.24% |
| 2014 Q1 | 1.49 Million USD | -24.9% |
| 2013 Q1 | 3.46 Million USD | -12.31% |
| 2013 FY | 1.98 Million USD | -49.69% |
| 2013 Q4 | 1.98 Million USD | -19.89% |
| 2013 Q3 | 2.48 Million USD | -16.56% |
| 2013 Q2 | 2.97 Million USD | -14.17% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | 3.95 Million USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | 3.95 Million USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 Q1 | 1025.00 USD | -95.51% |
| 2006 Q2 | 91.63 Thousand USD | 14.8% |
| 2006 FY | 22.8 Thousand USD | -78.62% |
| 2006 Q4 | 22.8 Thousand USD | -47.91% |
| 2006 Q3 | 43.78 Thousand USD | -52.22% |
| 2006 Q1 | 79.82 Thousand USD | -25.19% |
| 2005 Q4 | 106.7 Thousand USD | -20.12% |
| 2005 FY | 106.7 Thousand USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | 133.58 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q2 | 78.01 Thousand USD | -90.89% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q1 | 856.37 Thousand USD | 0.92% |
| 2001 FY | - USD | -100.0% |
| 2001 Q4 | - USD | 0.0% |
| 2000 FY | 848.57 Thousand USD | 69.72% |
| 2000 Q3 | 864.48 Thousand USD | 5.26% |
| 2000 Q4 | 848.57 Thousand USD | -1.84% |
| 2000 Q1 | 734.29 Thousand USD | 46.86% |
| 2000 Q2 | 821.28 Thousand USD | 11.85% |
| 1999 Q3 | 500 Thousand USD | -16.67% |
| 1999 Q2 | 600 Thousand USD | 0.0% |
| 1999 Q1 | 600 Thousand USD | -14.29% |
| 1999 FY | 500 Thousand USD | -28.57% |
| 1999 Q4 | 500 Thousand USD | 0.0% |
| 1998 FY | 700 Thousand USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | 800 Thousand USD | 0.0% |
| 1998 Q4 | 700 Thousand USD | -12.5% |
| 1998 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bright Green Corporation | 201.78 Thousand USD | -66.511% |
| Alpha Teknova, Inc. | 13.25 Million USD | 97.464% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.891% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.631% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.931% |
| Cosmos Health Inc. | 3.03 Million USD | 88.931% |
| Journey Medical Corporation | 14.62 Million USD | 97.702% |
| Embecta Corp. | 1.62 Billion USD | 99.979% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.933% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.867% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 97.479% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.935% |
| PainReform Ltd. | 30 Thousand USD | -1019.97% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 37.668% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 37.668% |
| SCYNEXIS, Inc. | 12.15 Million USD | 97.237% |
| Safety Shot Inc | 304.9 Thousand USD | -10.195% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -186.856% |
| Procaps Group, S.A. | 28.41 Million USD | 98.817% |
| Theratechnologies Inc. | 51.26 Million USD | 99.345% |
| Harrow Health, Inc. | 183.17 Million USD | 99.817% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -286.197% |
| Biofrontera Inc. | 804 Thousand USD | 58.21% |
| DURECT Corporation | 2.7 Million USD | 87.565% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 98.988% |
| Cronos Group Inc. | 1.55 Million USD | 78.448% |
| OptiNose, Inc. | 611 Thousand USD | 45.01% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.933% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 99.017% |
| RedHill Biopharma Ltd. | 455 Thousand USD | 26.156% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 99.447% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 97.372% |
| Radius Health, Inc. | 339.66 Million USD | 99.901% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 96.725% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.927% |
| Procaps Group S.A. | 28.41 Million USD | 98.817% |
| Alvotech | 1.02 Billion USD | 99.967% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 94.856% |
| Viatris Inc. | 16.18 Billion USD | 99.998% |
| Rockwell Medical, Inc. | 8.29 Million USD | 95.948% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 96.911% |
| Tilray Brands, Inc. | 287.93 Million USD | 99.883% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 99.721% |
| Shineco, Inc. | 10.01 Million USD | 96.646% |
| PetIQ, Inc. | 437.82 Million USD | 99.923% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -59.996% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.87% |
| Alimera Sciences, Inc. | 64.48 Million USD | 99.479% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 99.128% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -148.718% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 95.1% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | 53.335% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1394.356% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 98.974% |
| Hempacco Co., Inc. | 5.93 Million USD | 94.335% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.967% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 99.402% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.945% |
| Currenc Group, Inc. | 2.5 Million USD | 86.598% |
| Kamada Ltd. | 7.43 Million USD | 95.483% |
| Indivior PLC | 235.66 Million USD | 99.857% |
| Evoke Pharma, Inc. | 5 Million USD | 93.28% |
| Flora Growth Corp. | 942 Thousand USD | 64.332% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1394.356% |
| Evolus, Inc. | 120.35 Million USD | 99.721% |
| HUTCHMED (China) Limited | 48.18 Million USD | 99.303% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.943% |
| Akanda Corp. | 2.49 Million USD | 86.545% |